| 1 | Lilly (Eli) | $1.15 trillion | United States | 2: S&P 500, NYSE Composite |
| 2 | Johnson & Johnson | $654.1 billion | United States | 3: S&P 500, Dow Jones, NYSE Composite |
| 3 | AbbVie | $511.0 billion | United States | 2: S&P 500, NYSE Composite |
| 4 | Roche Holding AG | $381.8 billion | Switzerland | 1: SMI |
| 5 | UnitedHealth Group | $375.3 billion | United States | 2: S&P 500, Dow Jones |
| 6 | Merck & Co. | $357.2 billion | United States | 3: S&P 500, Dow Jones, NYSE Composite |
| 7 | Novartis International AG | $292.1 billion | Switzerland | 2: NYSE Composite, SMI |
| 8 | Thermo Fisher Scientific | $252.1 billion | United States | 2: S&P 500, NYSE Composite |
| 9 | AstraZeneca | $249.9 billion | United Kingdom | 3: FTSE 100, NYSE Composite, OMX Stockholm 30 |
| 10 | Amgen | $242.5 billion | United States | 4: S&P 500, Nasdaq-100, Dow Jones, Nasdaq Composite |
| 11 | Gilead Sciences | $197.6 billion | United States | 3: S&P 500, Nasdaq-100, Nasdaq Composite |
| 12 | Abbott Laboratories | $179.2 billion | United States | 2: S&P 500, NYSE Composite |
| 13 | Pfizer | $172.2 billion | United States | 2: S&P 500, NYSE Composite |
| 14 | Danaher Corporation | $163.6 billion | United States | 2: S&P 500, NYSE Composite |
| 15 | Intuitive Surgical | $161.1 billion | United States | 3: S&P 500, Nasdaq-100, Nasdaq Composite |
| 16 | Vertex Pharmaceuticals | $132.1 billion | United States | 3: S&P 500, Nasdaq-100, Nasdaq Composite |
| 17 | Bristol Myers Squibb | $126.4 billion | United States | 2: S&P 500, NYSE Composite |
| 18 | Medtronic | $121.8 billion | United States | 2: S&P 500, NYSE Composite |
| 19 | CVS Health | $121.0 billion | United States | 2: S&P 500, NYSE Composite |
| 20 | McKesson | $117.3 billion | United States | 2: S&P 500, NYSE Composite |
| 21 | Stryker Corporation | $116.7 billion | United States | 2: S&P 500, NYSE Composite |
| 22 | HCA Healthcare | $102.5 billion | United States | 2: S&P 500, NYSE Composite |
| 23 | Sanofi | $100.3 billion | France | 3: Euro Stoxx 50, CAC 40, Nasdaq Composite |
| 24 | Elevance Health | $95.6 billion | United States | 2: S&P 500, NYSE Composite |
| 25 | GSK | $94.3 billion | United Kingdom | 2: FTSE 100, NYSE Composite |
| 26 | EssilorLuxottica | $90.9 billion | France | 2: Euro Stoxx 50, CAC 40 |
| 27 | Regeneron Pharmaceuticals | $83.9 billion | United States | 3: S&P 500, Nasdaq-100, Nasdaq Composite |
| 28 | Cigna | $82.0 billion | United States | 2: S&P 500, NYSE Composite |
| 29 | Moderna | $80.0 billion | United States | 3: S&P 500, Nasdaq-100, Nasdaq Composite |
| 30 | Chugai Pharmaceutical Co., Ltd. | $72.1 billion | Japan | 1: Nikkei 225 |
| 31 | Merck | $69.8 billion | Germany | 1: DAX |
| 32 | Boston Scientific | $66.2 billion | United States | 2: S&P 500, NYSE Composite |
| 33 | CSL | $65.7 billion | Australia | 1: S&P/ASX 200 |
| 34 | Takeda Pharmaceutical Company Limited | $65.5 billion | Japan | 2: NYSE Composite, Nikkei 225 |
| 35 | Cencora | $63.7 billion | United States | 2: S&P 500, NYSE Composite |
| 36 | Cardinal Health | $58.5 billion | United States | 2: S&P 500, NYSE Composite |
| 37 | UCB | $57.3 billion | Belgium | 1: BEL 20 |
| 38 | Argenx | $55.5 billion | Netherlands | 3: Euro Stoxx 50, Nasdaq Composite, BEL 20 |
| 39 | Hoya Corp. | $55.2 billion | Japan | 1: Nikkei 225 |
| 40 | Galderma | $54.5 billion | Switzerland | 1: SMI |
| 41 | Becton Dickinson | $53.9 billion | United States | 2: S&P 500, NYSE Composite |
| 42 | Lonza Group AG | $53.5 billion | Switzerland | 1: SMI |
| 43 | Veeva Systems | $52.6 billion | United States | 2: S&P 500, NYSE Composite |
| 44 | Siemens Healthineers | $52.5 billion | Germany | 1: DAX |
| 45 | Edwards Lifesciences | $51.6 billion | United States | 2: S&P 500, NYSE Composite |
| 46 | Humana | $51.1 billion | United States | 2: S&P 500, NYSE Composite |
| 47 | Bayer | $50.0 billion | Germany | 2: Euro Stoxx 50, DAX |
| 48 | Agilent Technologies | $49.6 billion | United States | 2: S&P 500, NYSE Composite |
| 49 | IQVIA | $46.3 billion | United States | 2: S&P 500, NYSE Composite |
| 50 | Teva Pharmaceutical Industries | $46.2 billion | Israel | 2: NYSE Composite, TA-35 |
| 51 | Waters Corporation | $45.1 billion | United States | 2: S&P 500, NYSE Composite |
| 52 | Idexx Laboratories | $44.3 billion | United States | 3: S&P 500, Nasdaq-100, Nasdaq Composite |
| 53 | Sun Pharma | $43.9 billion | India | 1: Nifty 50 |
| 54 | Sandoz | $43.3 billion | Switzerland | 1: SMI |
| 55 | Otsuka Holdings Co., Ltd. | $41.6 billion | Japan | 1: Nikkei 225 |
| 56 | Haleon | $41.0 billion | United Kingdom | 2: FTSE 100, NYSE Composite |
| 57 | Illumina, Inc. | $40.9 billion | United States | 2: S&P 500, Nasdaq Composite |
| 58 | Biogen | $37.5 billion | United States | 2: S&P 500, Nasdaq Composite |
| 59 | ResMed | $35.7 billion | United States | 3: S&P 500, NYSE Composite, S&P/ASX 200 |
| 60 | Centene Corporation | $34.6 billion | United States | 2: S&P 500, NYSE Composite |
| 61 | Alcon Inc | $33.9 billion | Switzerland | 2: NYSE Composite, SMI |
| 62 | Mettler Toledo | $33.5 billion | United States | 2: S&P 500, NYSE Composite |
| 63 | Zoetis | $33.4 billion | United States | 2: S&P 500, NYSE Composite |
| 64 | Daiichi Sankyo Co., Ltd. | $32.7 billion | Japan | 1: Nikkei 225 |
| 65 | GE HealthCare | $32.3 billion | United States | 3: S&P 500, Nasdaq-100, Nasdaq Composite |
| 66 | Alnylam Pharmaceuticals | $30.6 billion | United States | 2: Nasdaq-100, Nasdaq Composite |
| 67 | Astellas Pharma Inc. | $29.2 billion | Japan | 1: Nikkei 225 |
| 68 | Dexcom | $29.0 billion | United States | 3: S&P 500, Nasdaq-100, Nasdaq Composite |
| 69 | West Pharmaceutical Services | $27.5 billion | United States | 2: S&P 500, NYSE Composite |
| 70 | Labcorp | $26.8 billion | United States | 2: S&P 500, NYSE Composite |
| 71 | Quest Diagnostics | $26.7 billion | United States | 2: S&P 500, NYSE Composite |
| 72 | Philips | $26.2 billion | Netherlands | 1: AEX |
| 73 | Incyte | $23.1 billion | United States | 2: S&P 500, Nasdaq Composite |
| 74 | Terumo Corp. | $22.7 billion | Japan | 1: Nikkei 225 |
| 75 | Steris | $22.6 billion | United States | 2: S&P 500, NYSE Composite |
| 76 | Sigma Healthcare | $22.1 billion | Australia | 1: S&P/ASX 200 |
| 77 | Viatris | $20.9 billion | United States | 2: S&P 500, Nasdaq Composite |
| 78 | Zimmer Biomet | $18.6 billion | United States | 2: S&P 500, NYSE Composite |
| 79 | Revvity | $17.9 billion | United States | 2: S&P 500, NYSE Composite |
| 80 | Charles River Laboratories | $16.9 billion | United States | 2: S&P 500, NYSE Composite |
| 81 | Shionogi & Co., Ltd. | $16.5 billion | Japan | 1: Nikkei 225 |
| 82 | Eurofins Scientific | $16.4 billion | France | 1: CAC 40 |
| 83 | Fisher & Paykel Healthcare | $16.3 billion | New Zealand | 2: S&P/ASX 200, S&P/NZX 50 |
| 84 | Orion | $15.2 billion | Finland | 1: OMX Helsinki 25 |
| 85 | Solventum | $14.8 billion | United States | 2: S&P 500, NYSE Composite |
| 86 | Pro Medicus | $14.8 billion | Australia | 1: S&P/ASX 200 |
| 87 | Baxter International | $13.1 billion | United States | 2: S&P 500, NYSE Composite |
| 88 | Recordati | $12.3 billion | Italy | 1: FTSE MIB |
| 89 | Fresenius Medical Care | $12.2 billion | Germany | 2: DAX, NYSE Composite |
| 90 | DaVita | $11.9 billion | United States | 2: S&P 500, NYSE Composite |
| 91 | Brightspring Health Services Inc | $11.9 billion | United States | 2: Russell 2000, Nasdaq Composite |
| 92 | Apollo Hospitals | $11.9 billion | India | 1: Nifty 50 |
| 93 | Olympus Corp. | $11.8 billion | Japan | 1: Nikkei 225 |
| 94 | Cooper Companies (The) | $11.7 billion | United States | 2: S&P 500, Nasdaq Composite |
| 95 | Cipla | $11.5 billion | India | 1: Nifty 50 |
| 96 | Dr. Reddy's Laboratories | $11.5 billion | India | 2: NYSE Composite, Nifty 50 |
| 97 | Smith & Nephew | $11.5 billion | United Kingdom | 2: FTSE 100, NYSE Composite |
| 98 | Bio-Techne | $11.4 billion | United States | 2: S&P 500, Nasdaq Composite |
| 99 | Universal Health Services | $11.1 billion | United States | 2: S&P 500, NYSE Composite |
| 100 | Align Technology | $10.9 billion | United States | 2: S&P 500, Nasdaq Composite |